News
Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV Four Scientific Posters Presented at EASL, ...
Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback